Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody, covering 2024-09-05 to 2024-09-05. Get the full timeline:
Most recent: Clinical Trial Update: 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy [Phase 2]